The FirstTake Podcast – A tale of two COVID-19 vaccines

FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss Pfizer’s projected COVID-19 vaccine revenues for 2021 and whether clinical data validates the commercial dominance of this product over AstraZeneca’s competing vaccine, look at Keytruda’s increasingly compelling profile as a treatment for early-stage and advanced triple-negative breast cancer (TNBC) and put Amgen’s acquisition of Teneobio under the spotlight.

Listen here on apple podcastsSpotify or Google.

To read more ViewPoints articles, click here.

Reference Articles